One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis

被引：0
|
作者：
Alessandro Inno
Sandro Barni
Antonio Ghidini
Alberto Zaniboni
Fausto Petrelli
机构：
[1] IRCCS Ospedale Sacro Cuore Don Calabria,Oncology Unit, Cancer Care Center
[2] ASST Bergamo Ovest,Oncology Unit, Medical Sciences Department
[3] Casa di Cura Igea,Oncology Unit
[4] Casa di Cura Poliambulanza,Oncology Unit
来源：
Breast Cancer Research and Treatment | 2019年 / 173卷
关键词：
Breast cancer; Adjuvant; Trastuzumab; Duration; One year;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：247 / 254
页数：7
相关论文
共 50 条
  • [41] Efficacy and safety of trastuzumab with or without a tyrosine kinase inhibitor for HER2-positive breast cancer: A systematic review and meta-analysis
    Li, Lixi
    Zhang, Di
    Wu, Yun
    Wang, Jiayu
    Ma, Fei
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (06):
  • [42] Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer: A Review of Clinical Data With Nursing Implications
    Palmieri, Frances M.
    Myatt, Charlyn V.
    Perez, Edith A.
    [J]. CLINICAL JOURNAL OF ONCOLOGY NURSING, 2010, 14 (03) : 326 - 336
  • [43] The Effect of Adding Pertuzumab to Adjuvant Trastuzumab in Early HER2-Positive Breast Cancer
    Al-Azawi, Ahmed
    Hneua, Riyadh Abd-Alrasool
    Hameed, Rana Majeed
    Hassan, Duha Maithem
    [J]. JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2023, 9 (03): : 197 - 200
  • [44] An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer
    Chen, Wen
    Jiang, Zefei
    Shao, Zhimin
    Sun, Qiang
    Shen, Kunwei
    [J]. VALUE IN HEALTH, 2009, 12 : S82 - S84
  • [45] Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients
    Mustacchi, G.
    Puglisi, F.
    Molino, A. M.
    Crivellari, D.
    Ghiotto, C.
    Ferro, A.
    Brunello, A.
    Saracchini, S.
    Turazza, M.
    Cretella, E.
    Iop, A.
    Malagoli, M.
    Stefani, M.
    [J]. FUTURE ONCOLOGY, 2015, 11 (10) : 1493 - 1500
  • [46] A BUDGET-IMPACT ANALYSIS OF ADJUVANT PERTUZUMAB AND TRASTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER
    Walter, E.
    Lazic-Peric, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S26 - S26
  • [47] Short versus long duration of adjuvant trastuzumab (T) in HER2+breast cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).
    Sipra, Qurat Ul Ain Riaz
    Bin Riaz, Irbaz
    Husnain, Muhammad
    Raina, Ammad
    Khan, Ahsan
    Akhtar, Maheen
    Wang, Zhen
    Murad, M. Hassan
    Leon-Ferre, Roberto Antonio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis
    Shen, Y.
    Fujii, T.
    Ueno, N. T.
    Tripathy, D.
    Fu, N.
    Zhou, H.
    Ning, J.
    Xiao, L.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (01) : 1 - 9
  • [49] Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Yu, Liuwen
    Fu, Fangmeng
    Li, Jing
    Huang, Meng
    Zeng, Bangwei
    Lin, Yuxiang
    Mei, Qian
    Lv, Jinxing
    Wang, Chuan
    [J]. JOURNAL OF ONCOLOGY, 2020, 2020
  • [50] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ
    Procter, M
    Leyland-Jones, B
    Goldhirsch, A
    Untch, M
    Smith, I
    Gianni, L
    Baselga, J
    Bell, R
    Jackisch, C
    Cameron, D
    Dowsett, M
    Barrios, CH
    Steger, G
    Huang, CS
    Andersson, M
    Inbar, M
    Lichinitser, M
    Láng, I
    Nitz, U
    Iwata, H
    Thomssen, C
    Lohrisch, C
    Suter, TM
    Ruschoff, J
    Süto, T
    Greatorex, V
    Ward, C
    Straehle, C
    McFadden, E
    Dolci, MS
    Gelber, RD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1659 - 1672
12345